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Alpha-synuclein (αSyn) is one of the key proteins considered to be involved 
in the pathogenesis of the Parkinson`s disease (PD) and being the main component of 
Lewy bodies (LBs). Studies on the αSyn gene mutants and overexpression of αSyn in 
yeast and rodent brains indicate that the level of αSyn in neurons is linked to 
dopaminergic neurons degeneration, and impairment of αSyn degradation is directly 
related to its aggregation in PD. However, the exact mechanism by which αSyn 
dysfunction and its degradation are regulated are not well established. 
Previous studies have suggested that both the ubiquitin-proteasome system 
(UPS) and the autophagy-lysosomal pathway (ALP) are involved in the degradation of 
αSyn, in which the ubiquitin (Ub) system plays an important role. Moreover, αSyn was 
found to bind Ub and the molecular chaperone 14-3-3 proteins, leading to enhanced 
αSyn aggregation. Our lab recently reported on elevated dopamine and 14-3-3 levels in 
the methionine sulfoxide reductase A (MsrA) knockout mouse brain, as well as 
decreased αSyn degradation in MsrA KO yeast cells. Hence, this study will focus on 
the interactions among MsrA, αSyn degradation, 14-3-3 proteins, and Ub.       
        Here we show that msrA overexpressing (OP) yeast cells extract promotes 
αSyn aggregation in a Ub- and ATP-dependent manner. Moreover, ubiquitin could 
promote clearance of both native and A53T mutant αSyn monomers in the presence of 
msrA OP extract in comparison to a msrA null mutant yeast extract. Furthermore, MsrA 
was found to inhibit the auto-ubiquitination of Parkin (a known E3 ubiquitin ligase of 
αSyn). These data suggest that MsrA plays an important role in ubiquitin-dependent 
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αSyn degradation and may function as an E3 Ub ligase. To explore the interactions 
between αSyn, MsrA, and Ub-bound proteins, a mammalian ex-vivo system was 
designed using wild-type (W) and MsrA knockout (M) mouse brain extracts. Following 
pull-down experiments using His-tagged Ub and the mouse brain extracts, it was 
determined that 14-3-3 proteins were ubiquitinated with dependency on the presence of 
MsrA (W brain) and ATP. Immunoprecipitation experiments using anti-Ub antibody 
revealed that M brain exhibited lower levels of ubiquitinated and degraded band 
products of both αSyn and 14-3-3 proteins, compared with W brain. Complementary 
immunoprecipitation experiments using anti-14-3-3 antibody showed an enhanced 
αSyn degradation and ubiquitination in the presence of ATP in W versus M brain 
extracts, suggesting that 14-3-3 interacts with MsrA and the Ub-system to enhance 
αSyn degradation. Last but not least, an ex-vivo study performed in yeast cells (wild-
type and msrA null mutant strains overexpressing A53T αSyn) showed that the msrA 
mutant strain possessed significantly much lower total and αSyn ubiquitination levels 
compared with the wild-type strain. These observations suggest that MsrA plays an 
important role in the ubiquitination and degradation of αSyn through the ubiquitin-
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  CHAPTER 1: INTRODUCTION 
1.1. Parkinson’s Disease and Dopamine 
1.1.1. Parkinson’s Disease  
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder in the world. As many as 10 million people worldwide are living with PD, in 
which about 60% patients are male. The mean age of PD’s onset is 55, and the incidence 
increases markedly with age [1]. In the United States alone, the combined direct and 
indirect costs of PD are estimated to be near $25 billion per year [2]. 
Parkinson’s disease is now recognized to be a heterogeneous 
neurodegenerative syndrome with motor and non-motor symptoms [3]. The motor 
symptoms are characterized by a combination of rigidity, bradykinesia, tremor and 
postural instability. On the other hand, common non-motor symptoms in PD relate to 
cognitive dysfunction, affective disorders, abnormalities of autonomic function, 
personality changes, sleep disorders, and sensory complaints or pain [4]. Although it 
has been known for some time that genetic factors can be involved in some cases, there 
is no apparent genetic linkage in most of the PD cases [5]. Like other neurodegeneration 
diseases, PD is generally progressive, leading to increasing disability unless effective 
treatment is provided. 
1.1.2. Dopamine and Parkinson’s disease 
Dopamine (DA) functions as a neurotransmitter in the central nervous system 
(CNS). DA pathways are involved in reward-motivated behavior, motor control and the 
release of various hormones. The loss of dopaminergic neuronal cells in the substantia 
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nigra pars compacta (SNpc), which results in DA loss in the basal ganglia (an area of 
the brain responsible for coordinating fine motor control) is one of the main features of 
PD [6]. One hypothesis proposes that mitochondrial dysfunction and the consequent 
oxidative stress, including toxic oxidized DA species, lead to the death of SNpc 
neuronal cells. Molecular studies found that dopaminergic neurons are very vulnerable 
to oxidative stress, as the metabolism of DA produces hydrogen peroxide and 
superoxide radicals [7]. Besides, mitochondria-related energy failure may disrupt 
vesicular storage of DA, leading to increasing free cytosolic DA concentration, 
allowing harmful DA-mediated reactions to damage cellular macromolecules [8]. 
Recent studies have revealed that DA oxidation to dopamine o-quinone, aminochrome, 
and 5,6-indolequinone seems to play an important role in the neurodegenerative 
processes of PD through (i) mitochondrial dysfunction, (ii) aggregation of misfolded 
proteins, (iii) protein degradation dysfunction and (iv) generation of reactive oxygen 
species (ROS) [9].  
1.1.3. L-DOPA Therapy 
Following the observation that the levels of DA are severely reduced in the 
striatum of patients with PD, researchers found that L-3,4-dihydroxyphenylalanine (L-
DOPA), a precursor of DA that crosses the blood-brain barrier, can restore brain DA 
and motor function in an animal model [10]. Soon attempts were made to alleviate the 
symptoms of PD through the administration of L-DOPA, which gave birth to the L-
DOPA therapy. To this day, this therapy remains the cornerstone of PD symptoms’ 
control but it has a lot of limitations. For example, it is only a symptomatic treatment, 
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and its efficacy tends to decrease with the disease progression. 
1.2.  Lewy Body and Alpha-synuclein 
1.2.1. Lewy Body and Parkinson’s Disease 
The pathological hallmarks of PD are the loss of the nigrostriatal 
dopaminergic neurons and the presence of insoluble intraneuronal proteinaceous 
cytoplasmic inclusions, termed “Lewy Bodies (LBs)”. LBs are spherical eosinophilic 
protein aggregates composed of numerous proteins, including alpha-synuclein (αSyn), 
parkin, ubiquitin (Ub), and neurofilaments. The major component of Lewy bodies is 
αSyn [11]. One hypothesis for LB formation is that αSyn monomers become oligomers 
(protofibrils), which coalesce into fibrils and then aggregate into Lewy body inclusions 
[12]. Besides Parkinson’s disease, LBs were also found in patients with diffuse Lewy 
body disease (DLBD), Lewy body dementia (LBD) and multiple system atrophy (MSA) 
[13]. These observations show that Lewy body pathology may affect different subtypes 
of neurons as well as glia, and they also indicate that additional factors other than Lewy 
pathology alone might be required for αSyn’s toxicity in patients. 
1.2.2. Alpha-synuclein (αSyn) 
1.2.2.1. Structure  
The first link between αSyn and PD was made when the identification of a 
missense mutation on chromosome 4 was linked to an autosomal-dominant inherited 
form of PD [14]. Since then, the research interest in this protein has grown rapidly. 
αSyn is expressed in all vertebrates. Human αSyn is a 140-amino acids protein (Figure 
1A), and it belongs to the synuclein family that consists of three subtypes: alpha, beta, 
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and gamma. The synucleins are similar in sequence, with most of the similarity lying 
within the N-terminus of the proteins [15]. A structure of the full-length, membrane-
bound form of human αSyn was revealed through nuclear magnetic resonance (NMR) 
spectroscopy (Figure 1B). Homology of αSyn across species is greater at the N-
terminus of the protein, with more variability in sequence located toward the C-
terminus. N-terminal point mutations in αSyn (A30P, E46K, H50Q, G51D, A53E and 
A53T) [11, 16-21] and genomic duplications or triplications that contain the αSyn locus 
result in autosomal dominant forms of familial PD [22, 23]. Within cells, αSyn is highly 
soluble and intrinsically disordered under normal conditions. However, in the presence 
of acidic lipid membranes or membranes with high curvature, the N-terminus of αSyn 
folds into an alpha-helix that interacts with membranes [24, 25]. Moreover, under 
certain circumstances, the protein can undergo a profound conformational transition to 
a β-sheet–rich structure that polymerizes to form toxic oligomers and or amyloid 
structure in the fibrils that compose Lewy bodies [26]. The β-pleated conformation 
binds other proteins such as synphilin-1 [27], parkin [28] and the anti-apoptotic 




Figure 1. Human αSyn sequence and structure (A) Human αSyn sequence (accession 
number P37840.1) (B) Structure of human micelle-bound αSyn (determined by NMR, PDB ID: 
1XQ8) 
 
1.2.2.2. ΑSyn and Neurotoxicity 
αSyn is expressed predominantly in the central nervous system and localizes 
to presynaptic terminals. The expression level of αSyn is up to 1% of the total protein 
in certain regions of the brain [30]. Within neuronal cells, αSyn has been detected in 
both the cytoplasm and nucleus [31]. Studies utilizing fractionated rat brains revealed 
that about 15% of αSyn is membrane-bound [32], and the protein was recently found 
associated with mitochondrial membranes in normal dopaminergic neurons [33]. The 
relative subcellular distribution of αSyn varies among different neuronal cell 
populations [34]. 
The exact function of αSyn has not been established, and the roles of the 
various physical forms of αSyn in PD pathogenesis are still controversial. αSyn-
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knockout mice, are viable and have normal synaptic architecture and brain morphology, 
suggesting that other proteins may play a redundant role in the cell [35]. On the other 
hand, the high correlation between αSyn burden and PD has led to the hypothesis that 
αSyn aggregation produces toxicity through a gain-of-function mechanism. However, 
αSyn has been implicated to function in a diverse range of essential cellular processes 
such as the regulation of neurotransmission and response to cellular stress [36]. These 
findings add on to the complexity of the relationship between αSyn and dopaminergic 
neurons. 
Despite the divergence on the actual biological function of αSyn, there is a 
consensus that the dysfunction of αSyn results in its toxicity. To be more specific, the 
misfolding and aggregation of αSyn are vital in the death of SNpc dopaminergic 
neurons (figure 2). Although αSyn normally localizes to the presynaptic terminal, its 
oligomers and aggregates distribute throughout the cell body and neurites, which 
suggests that αSyn might disrupt cellular function beyond the presynaptic terminal. 
Indeed, multiple organelles are implicated in αSyn toxicity, showing that aggregated or 
soluble misfolded αSyn can be neurotoxic through a variety mechanisms:  
Synaptic-vesicle trafficking: αSyn regulates soluble N-ethylmaleimide- 
sensitive factor（NSF） attachment protein receptor (SNARE) complex assembly by 
binding the SNARE protein synaptobrevin-2/vesicle-associated membrane protein 2 
(VAMP2) to promote synaptic vesicle fusion at the presynaptic terminal [37]. It also 
potentially regulates additional steps during synaptic vesicle trafficking [38]. 
Mitochondrial function: Mitochondria are crucial for ATP synthesis, 
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calcium storage, lipid metabolism and neuronal survival. αSyn toxicity might directly 
or indirectly disrupt mitochondrial homeostasis [39]. Besides, in αSyn knockout mice, 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced degeneration of 
dopaminergic neurons is prevented [40], probably because αSyn oligomers promote 
mitochondrial dysfunction via increased calcium uptake [41]. 
Endoplasmic reticulum and Golgi function, and the endocytic pathway: 
The endoplasmic reticulum (ER) is essential for protein folding, trafficking to the Golgi, 
calcium buffering and the unfolded protein response (UPR). Both wild-type and mutant 
αSyn disrupt ER to Golgi trafficking in yeast [42]. Increased αSyn expression also 
disrupts endosomal transport events via the E3 ubiquitin ligase in yeast [43]. Moreover, 
increased αSyn levels also raise cytoplasmic calcium levels, which leads to the 
activation of a toxic calmodulin–calcineurin cascade [44], suggesting that calcium 
buffering in the ER might be disrupted by αSyn. 
Autophagy or lysosomal pathway: Autophagy is a dynamic pathway 
involved in the degradation of damaged organelles and protein aggregates [45]. αSyn 
overexpression disrupts ER to Golgi trafficking of the autophagic transmembrane 
protein ATG9 and decreases the formation of omegasomes, a precursor for 
autophagosome biogenesis [46]. 
Dysregulation of inter-organelle contacts and organelle dynamics: In the 
past few years, multiple inter-organelle contacts have emerged as sites of cellular 
homeostatic regulation. Mitochondria-associated ER membrane (MAM), a subdomain 
of the ER tethered to mitochondria via a group of adaptor proteins, which serves as a 
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critical site for autophagosome biogenesis, mitochondrial fission, calcium homeostasis, 
phospholipid transport and fatty acid and cholesterol transfer [47], is significantly 
increased after αSyn overexpression, resulting in increased mitochondrial calcium 
uptake from the ER and mitochondrial fragmentation [48]. Moreover, αSyn fibrils were 
found to impair the axonal transport of autophagosomes and RAB7- and TrkB-receptor-
positive endosomes [49]. Further investigation of αSyn in the dynamic organelle 




Figure 2. Simplified model of αSyn neurotoxicity 
 
1.3. Ubiquitination and Protein Degradation Pathways in Parkinson’s disease 
Protein misfolding, aggregation, and deposition are common disease 
mechanisms shared by many neurodegenerative diseases. In PD, αSyn accumulates to 
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form Lewy bodies and Lewy neurites. Given that no consistent alternations in αSyn 
mRNA levels have been found in sporadic PD [50], impaired αSyn degradation is very 
likely to account for the accumulation of this protein in disease states. In neurons, the 
two major that participate in the clearance of altered proteins are the ubiquitin-
proteasome system (UPS) and the autophagy-lysosomal pathway (ALP). Both 
pathways are involved in the degradation of αSyn [51]. 
1.3.1. Ubiquitin-proteasome System Dysfunction 
       The UPS is the major pathway that mediates the degradation of soluble 
intracellular proteins in the cytoplasm, nucleus and endoplasmic reticulum (ERAD) 
[52]. The clearance of proteins by the UPS involves a certain sequence of events: First, 
ubiquitin (Ub), a small and stable globular protein, is activated in an ATP-dependent 
reaction by the E1 enzyme, which forms a thioester with the ubiquitin C-terminus, and 
is then transferred to the active site cysteine of the E2 enzyme to yield an E2~Ub 
thioester intermediate. The E3 ligase binds to both the E2~Ub thioester and the substrate, 
catalyzing the transfer of the ubiquitin from the active site cysteine of the E2 to the 
substrate lysine or N-terminus [53]. This ubiquitination process results in a covalent 
link between a chain of activated ubiquitin monomers and the lysine residues of the 
substrate protein. The ubiquitin chain serves as a signal for recognition by the 
proteasome. Proteasomal degradation yields short peptide fragments that are then 
subjected to further degradation by peptidases, allowing the recycling of amino acids 
for the synthesis of new proteins [52]. 
In some PD models, the inhibition of proteasome causes dose-dependent 
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neurodegeneration and the formation of Ub- and αSyn-positive inclusions [54-56]. In- 
vivo studies show that toxin-induced proteasome inhibition was found to cause neuronal 
cell loss in the SN, DA depletion in the striatum and even a disease phenotype. However, 
the UPS impairment was significantly alleviated in mice lacking αSyn, suggesting that 
αSyn exacerbates the deleterious effects of MPTP on the UPS [57]. Furthermore, a few 
studies showed that increased levels of αSyn can lead to impaired proteasome function. 
This mutual interaction between αSyn and proteasome function suggests that increased 
αSyn levels impair UPS, which can, in turn, lead to further αSyn accumulation. 
1.3.2. Autophagy Dysfunction 
        The autophagy-lysosomal pathway or autophagy is the general term used to 
describe pathways that converge into the degradation of intracellular proteins or 
organelles in lysosomes [52]. The essential component of this proteolytic system are 
the lysosomes, single membrane vesicles that contain in their lumen the larger variety 
of cellular hydrolases including proteases, lipases, glycosidases, and nucleotidases. In 
ALP, the mechanism of target recognition and delivery can be divided into three distinct 
categories: macroautophagy, microautophagy, and chaperone-mediated autophagy 
(CMA) [58]. Although autophagy has long been viewed as a random cytoplasmic 
degradation system, with the identification of autophagic-ubiquitin receptors, the roles 
of Ub and Ub-binding proteins in selective autophagy are emerging. 
        In PD patients, the accumulation of autophagic vacuoles was found in the SN. 
This accumulation is consistent with either an overproduction (as would be the case 
following primary UPS failure or as a secondary phenomenon to neurodegenerative 
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changes) or impaired turnover of autophagic vacuoles (as would be the case with 
primary ALP dysfunction or secondary dysfunction due to neurodegenerative changes) 
[59]. Besides, an increase of the autophagosome marker LC3-II and a decrease of the 
lysosomal marker LAMP-1 were identified in both tissues of PD and DLB patients, 
suggesting the presence of abundant and dysfunctional autophagosomes and lysosomes 
in synucleinopathies (reviewed in [51]). 
1.3.3. Degradation of Alpha-synuclein 
        Given the fact that αSyn aggregation plays a central role in the formation of 
LBs and PD pathogenesis, therapeutic strategies that aiming at the degradation of αSyn 
draws growing attention. However, the precise mechanisms of αSyn clearance in cells 
are not well established. Current studies suggest that both the UPS and the ALP are 
involved in the degradation of human wild-type αSyn. In addition, mutant A53T and 
A30P αSyn, as well as Serine129 phosphorylated αSyn were found to be degraded by 
both the UPS and macroautophagy (reviewed in [51]).  
1.4. 14-3-3 Proteins, DA Synthesis and Neurodegeneration 
        14-3-3 proteins form a family of highly conserved, acidic, dimeric proteins 
with a subunit mass of approximately 28 kDa. This class of proteins has been found in 
all eukaryotic organisms studied so far [60]. The highest tissue concentration of 14-3-3 
proteins is found in the brain (up to 1% of total soluble protein) and being present in 
the cytoplasmic compartment, plasma membrane and in intracellular organelles [61]. It 
is acknowledged that 14-3-3 proteins interact with various binding partners, including 
protein kinases, receptor proteins, enzymes, structural and cytoskeletal proteins, 
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proteins involved in cell cycle, transcriptional control and apoptosis [60]. In many but 
not all cases, 14-3-3 proteins bind to the phosphorylated forms of these proteins. The 
function of 14-3-3 proteins in these cellular processes is not entirely clear yet. However, 
more and more evidence suggests their role in enzyme regulation, control of protein 
subcellular localization and protein-protein interactions [60, 62]. Interestingly, 
immunohistochemical investigation of Lewy bodies showed intense positive 14-3-3 
staining in PD patients. Here the involvement of 14-3-3 proteins in DA synthesis and 
neurodegeneration will be discussed. 
        The rate-limiting enzyme in DA synthesis is tyrosine hydroxylase (TH) [63]. 
Upon TH activation by phosphorylation, 14-3-3 proteins bind to TH and inhibit its 
dephosphorylation, leading to prolonged stimulation of TH [64, 65].  
        αSyn was also shown to bind to 14-3-3 proteins [66]. Normally, αSyn binds 
to dephosphorylated TH and reduce its activity, whereas the binding of 14-3-3 proteins 
to phosphorylated tyrosine hydroxylase enhances DA production [61]. In the case of a 
reduction of αSyn due to sequestration of the protein, 14-3-3 protein-induced DA 
production could overwhelm the cell with cytosolic DA, with the subsequent generation 
of quinones and ROS [67], which may, in turn, lead to the misfolding and aggregation 
of αSyn. 
1.5. Methionine Sulfoxide Reductase A and αSyn degradation 
In proteins, except cysteine, methionine (Met) is also a sulfur amino acid 
(Met), which is converted to methionine sulfoxide (MetO) following exposure to 
reactive oxygen species (ROS), in which their production is increased during oxidative 
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stress conditions. Methionine sulfoxide reductase (Msr) catalyzes the reduction of 
MetO in proteins to Met and it is proved to play a critical role in the antioxidant 
response. Two subtypes of Msr exist in nature, MsrA that is specific for S-MetO, and 
MsrB that is specific for R-MetO [68]. There is one type of MsrA and three types of 
MsrB and MsrA is a positive regulator of MsrB expression [69].  
Oxidative stress mediated protein misfolding and aggregation is thought to 
play a major role in the pathogenesis of PD. It has been previously reported that the 
overexpression of αSyn could lead to a down-regulation of αSyn degradation in an ex-
vivo system, in which αSyn forms are expressed in msrA null yeast cells [70]. In 
addition, oxidation of methionine/s of αSyn was shown to inhibit its phosphorylation, 
in vitro, which is required for αSyn UPS-dependent degradation [70]. Consistent with 
these findings, recent studies demonstrated that MsrA suppresses dopaminergic cell 
death and protein aggregation induced by the complex I inhibitor rotenone or mutant 
αSyn [71]. Moreover, in a Drosophila model, MsrA was shown to inhibit the 
development of locomotor and circadian rhythm defects caused by ectopic expression 
of human αSyn [72]. 
Interestingly, accumulative evidence from bacterial organism suggests that 
MsrA is involved in the regulation of Ub-dependent protein degradation (unpublished 
data). In addition, earlier studies in our lab revealed an elevated 14-3-3 level in a MsrA 
knockout mouse model [73]. Through the incorporation of every component discussed 
earlier (αSyn, ubiquitination, 14-3-3 proteins, MsrA), a hypothesis of MsrA and Ub-
dependent degradation of αSyn is proposed in the next section. 
14 
 
1.6. Statement of Hypothesis 
Hypothesis: Methionine sulfoxide reductase A plays an important role in 

















CHAPTER 2: MATERIALS AND METHODS 
2.1. MsrA-dependent αSyn mass modification 
Three types of yeast strains (Saccharomyces cerevisiae, wild-type (WT), 
msrA null (KO) and msrA overexpression (OP)) were made and grown in synthetic 
minimal media as previously reported [74]. Mid-logarithmic cells were taken from the 
culture and resuspended in 1X PBS with yeast protease inhibitors cocktail (Cat# P8215-
1ML, Sigma) and MG132 proteasome inhibitor (Cat# BML-P1102-0005, Enzo), then 
extracted by glass beads and a bead-beater homogenizer apparatus (BioSpec Products, 
Bartlesville, OK, USA). Bradford protein assay was performed to measure total protein 
concentration of the three yeast extracts. The optical density was read at 595 nm with 
an iMark microplate reader (BIO-RAD, USA). Equal amounts of extracted proteins of 
each yeast type were incubated for a period of 30 minutes at 37°C in the presence of 
one of the three synucleins (native αSyn (Cat# CF66, Novoprotein), A53T mutant of 
αSyn, or A30P mutant of αSyn), human ubiquitin (U5507-1MG, Sigma), 10mM ATP 
and MgCl2 (In this study, ATP and MgCl2 are always used as a combination). At the end 
of the incubation, the extracts were diluted with 5X SDS-PAGE sample buffer and 
subjected to Western blot analysis using αSyn polyclonal antibody (PA5-17239, 
Invitrogen). All the immunoblot assays in this study are conducted using following 
supplies: Novex WedgeWell 4-20% Tris-Glycine Gel (Cat# XP04200BOX, Invitrogen), 
BupH Tris-Glycine Buffer Pack (Cat# 28380, Thermo), other necessary buffer are made 
following lab protocols. Control experiments were performed with the same procedure 




2.2. Degradation of αSyn in an ex-vivo system of yeast 
Yeast extracts of either msrA null (KO) or msrA overexpression (OP) were 
collected as described in 2.1 and incubated with two synuclein types: native (N) or 
A53T mutant (A53T) for a period of 30 minutes at 37°C, in the presence or absence of 
ubiquitin (Ub, which contained also ATP and MgCl2). At the end of the incubation, the 
extracts were diluted with 5X SDS-PAGE sample buffer and subjected to Western blot 
analysis using αSyn polyclonal antibody (PA5-17239, Invitrogen). 
2.3. Competition on Parkin auto-ubiquitination by MsrA 
Recombinant proteins were added to a reaction mixture as follows: 5µM of 
yeast His-tag MsrA (previously expressed and purified in the lab), 10µM ubiquitin 
(U5507-1MG, Sigma), 0.9mg/mL Parkin, 22nM E1, 1.4µM E2 (Parkin and 
corresponding E1, E2 enzymes were gifts from Dr. Richter from the Department of 
Molecular Bioscience at KU), and 1µg native αSyn (Cat# CF66, Novoprotein). The 
reaction mixture buffer contained 50mM Tris-HCl (pH 8.0), 1mM DTT, 4mM ATP, 
120mM NaCl2, and 5mM MgCl2. The reaction mixtures were incubated for a period of 
30 min at 37°C.  At the end of the incubation, the extracts were diluted with 5X SDS-
PAGE sample buffer and subjected to Western blot analysis using ubiquitin monoclonal 
antibody (Cat# BML-PW0930-0100, Enzo). 
2.4. Detection and identification of ubiquitinated proteins in wild-type and 
MsrA knockout mouse brains 
Wild-type (W) and MsrA knockout (M) mouse whole brain extracts were 
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made in PBS in the presence of protease inhibitors cocktail (Cat# P8215-1ML, Sigma) 
and MG132 proteasome inhibitor (Cat# BML-P1102-0005, Enzo). Bradford protein 
assay was performed to measure total protein concentration of the three yeast extracts. 
The optical density was read at 595 nm with an iMark microplate reader (BIO-RAD, 
USA). Equal amounts of protein extracts were incubated with recombinant His-tagged 
human ubiquitin (U5507-1MG, Sigma) with 10mM ATP and MgCl2 for or a period of 
30 min at 37°C. A control experiment was performed with the same procedure but 
without adding ATP or MgCl2. At the end of the incubation, the reaction mixture was 
added to 50µl of pre-washed His-Tag Purification Nickel Resin (Cat# 05893682001, 
Roche) for a 1 hour incubation at room temperature. Next, the binding mixture was 
centrifuged at 500rpm for 3 min at 4°C. The pellet was washed with 1X PBS for 5 times 
and eluted with elution buffer containing 100mm imidazole, 0.1M EDTA, and 5X SDS-
PAGE sample buffer. The eluate was subjected to Western blot analysis using ubiquitin 
monoclonal antibody (Cat# BML-PW0930-0100, Enzo). Another gel (with same 
samples loaded) were stained using coomassie blue for 15 min and washed extensively 
with distaining solution (40% methanol and 10% glacial acetic acid). The band that 
corresponded to a 36kDa ubiquitinated band in Western blot analysis was carefully 
separated. In-gel tryptic digestion followed by mass-spectrometry analysis were 
performed on resulting peptides for the identification and sequence determination of 
the target protein band (these analyses were performed according to established 
protocols by the KUMC mass-spectrometry core lab).  
2.5. Interactions between ubiquitin, αSyn, 14-3-3 proteins in wild-type and 
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MsrA knockout mouse brains 
Immunoprecipitation was conducted using 500µg protein of whole brain 
extract from wild-type (W) or MsrA knockout (M) mouse brain, prepared as described 
above. The brain extracts were incubated with recombinant human ubiquitin, A53T 
αSyn, 1X PBS, 10mM ATP and MgCl2 for 20 min. At the end of the incubation, the 
reaction was stopped on ice. Next, 10µl of anti-14-3-3 antibody (Cat# NB100-2140, 
NOVUS) was added to the reaction mixture and incubated at room temperature for 1 
hour. Then the sample was added to 20µl of pre-washed protein G sepharose (Cat# 28-
9440-08, GE Healthcare) and rotated at 4°C for overnight. The protein G beads-immune 
complex was centrifuged at 500rpm for 3 minutes at 4°C. The pellet was washed with 
1ml ice-cold 1X PBS 5 times. After washing, the proteins were eluted from the immune 
complexes 5X SDS-PAGE sample buffer with β-mercaptoethanol. The eluate was 
loaded onto SDS-PAGE gels for Western blot analysis using anti-αSyn antibody (Cat# 
610786, BD Transduction Laboratories) and anti-ubiquitin antibody (Cat# BML-
PW0930-0100, Enzo). Immunoprecipitation was also conducted following the same 
procedure while using instead an anti-ubiquitin antibody (Cat# BML-PW0930-0100, 
Enzo) and detected with an αSyn polyclonal antibody (PA5-17239, Invitrogen) or anti-
14-3-3 antibody (Cat# NB100-2140, NOVUS). 
2.6. Expression and purification of A53T αSyn in yeast and its effect on the 
organism’s protein ubiquitination  
The mutant A53T αSyn were expressed in wild-type (WT) and msrA null (KO) 
Saccharomyces cerevisiae strains with the pYES6 expression vector used previously 
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[70]. This vector harbors the yeast GAL1 promoter for high-level inducible protein 
expression by galactose. It has a C-terminal peptide encoding a V5 epitope and a 
polyhistidine (6His) tag for detection and purification of the recombinant fusion αSyn. 
This vector contains the ampicillin and blasticidin resistance genes for selection of 
bacteria and yeast colonies harboring the plasmid, respectively. The yeast cells were 
grown in synthetic complete medium without leucine for 36 hours and then transferred 
to induction media containing 2% galactose and 1% raffinose for a two-hour induction. 
Next, cell extracts were made as described in section 2.1.  
The expressed His-αSyn protein in each yeast strain was purified by nickel 
resin chromatography. Soluble protein extract of each packed yeast cells was incubated 
with 50µl of pre-washed His-Tag Purification Nickel Resin (Cat# 05893682001, Roche) 
for 1 hour at room temperature. Then, the resin was washed several times with PBS for 
and the His-A53TαSyn was eluted with 50µl elution buffer containing: 100mm 
imidazole, 0.1M EDTA, and 5X SDS-PAGE sample buffer. The eluate was subject to 
Western blot analysis with anti-αSyn antibody (Cat# 610786, BD Transduction 
Laboratories) and anti-ubiquitin antibody (Cat# BML-PW0930-0100, Enzo). In 
addition, protein extracts of both yeast strains expressing His-A53T αSyn were also 








CHAPTER 3: RESULTS 
3.1. MsrA-dependent αSyn mass modification 
To investigate the effects of MsrA on native αSyn and its point mutation 
variants (A30P, A53T), an ex-vivo system was designed in which the extracts of three 
types of yeast strains (wild-type (WT), msrA null (KO), and msrA overexpression (OP)) 
were incubated for a period of 30 minutes at 37°C in the presence of one of the 
synucleins, human ubiquitin, 10mM ATP and 10mM MgCl2. The mass modification of 
αSyn was detected by Western blot analysis (Figure 1). Since the UPS is inhibited in 
this system by the protease and proteasome inhibitors, this figure shows the mass-
accumulation pattern of the added synucleins. The msrA OP strain shows a high level 
of aggregation in all types of synuleins. However, only little aggregation is presented 
in msrA KO strain (Figure 1A), indicating that MsrA may play a role in the mass 
modification of αSyn. There is no significant difference between WT cells and msrA 
KO cells in the aggregation pattern of native αSyn or A30P αSyn (Figure 1A), 
presumably due to (i) low expression level and activity of MsrA in WT yeast cells [74] 
and (ii) native and A30P αSyn have a lower capacity of forming aggregates [42]. The 
relatively high MsrA level in msrA OP yeast cells may promote the aggregation of A30P 
αSyn either by enhancing its oligomerization due to ubiquitination or by strengthening 
its interaction with other cellular protein components. To evaluate the role of 
ubiquitination in the mass modification of αSyn, comparative experiments were done 
following similar idea but without adding ATP or Ub. msrA KO and msrA OP cells were 
used in these experiments because they share the same genomic background [74]. 
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Strong aggregation is observed only in msrA OP strain incubated with both ATP and Ub 
(Figure 1B, 1C), suggesting that both ATP and ubiquitination are involved in the mass 
modification of αSyn.  
3.2. Degradation of αSyn in an ex-vivo system of yeast 
Given the fact that both UPS and autophagy pathways contribute to the 
degradation of soluble αSyn monomers and ubiquitination events may be directly or 
indirectly involved in αSyn clearance, we further investigated the effect of ubiquitin on 
αSyn degradation with an ex-vivo system. Western blot analysis reveals that ubiquitin 
promotes the clearance of both types of αSyn (native and A53T) monomers in msrA OP 
strain, while msrA KO strain only shows slightly enhancement of A53T dimer 
degradation (Figure 2). These findings are consistent with the previous report that 
MsrA suppresses protein aggregation induced by mutant αSyn in dopaminergic neuron 
cells [71], suggesting that (i) both ubiquitin and MsrA are involved in αSyn degradation, 
(ii) multiple degradation pathways are involved in the clearance of the different forms 
of αSyn. It is noteworthy that, compared with msrA KO extract, an enhanced αSyn 
dimer clearance was observed for both native and A53T αSyns in the presence of msrA 
OP extract without the addition of Ub and ATP (Figure 2). However, addition of Ub 
and ATP only increased the degradation of the A53T αSyn dimer in extracts of both 
yeast strains (Figure 2). This observation may suggest that the dimers of native and 
A53T αSyn are differently recognized by proteolytic pathways that may possess also 
different dependency on MsrA, Ub or both (Figure 2). Interestingly, in the msrA OP 
strain, decreased native αSyn dimer degradation was observed when external ubiquitin 
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was added to the reaction mixture. This phenomenon further supports the idea that the 
degradation pathways of αSyn monomers and dimers are not the same. A possible 
overall explanation for these data is that MsrA has dual function active site, as follows : 
in the absence of external ubiquitin, MsrA functions mainly as a reductase, which may 
promote the degradation of αSyn dimers; while when the system is supplied with ample 
ubiquitin and ATP, the active site of MsrA is mainly occupied with ubiquitin (instead 
of MetO) and this might contribute to the enhanced degradation of αSyn monomers 
(The MetO reduction and Ub binding of Archaea MsrA is carried out by the same active 
site, unpublished data). 
3.3. Competition on Parkin auto-ubiquitination by MsrA 
The data presented above suggest that both ubiquitin and MsrA are involved 
in the degradation pathways of αSyn. In order to determine if these two factors directly 
interact with each other, an in-vitro system was created in presence of the parkin protein. 
Parkin has an E3 ubiquitin ligase activity and is believed to directly or indirectly 
mediate proteasomal degradation of aggregation-prone proteins, including αSyn. 
Moreover, mutations in the Parkin gene are the most common cause of hereditary 
parkinsonism [75]. In agreement with previous finding [75], Parkin showed a strong 
tendency of auto-ubiquitination. Surprisingly, this auto-ubiquitination disappeared 
when MsrA is introduced to the system (Figure 3). This result suggests that MsrA 
inhibits the binding between Parkin and Ub, possibly through competing for Ub binding 
(auto-ubiquitination of MsrA was not observed (data not shown) in this in-vitro system). 
It is yet to be determined what are the other factors that are needed for stabilizing the 
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complex between MsrA and Ub. Overall, based on the data presented under sections 
3.1 and 3.2, it is suggested that MsrA has a direct interaction with ubiquitin and may 
function as an E3 Ub ligase. 
3.4. Detection and identification of ubiquitinated proteins in wild-type and MsrA 
knockout mouse brains 
        The potential relationships between ubiquitination and αSyn degradation 
sought us to examine if similar interactions exist also in mouse brain. Wild-type (W) 
and MsrA knockout (M) mouse whole brain extracts were made in the presence of 
proteasome and protease inhibitors. After incubation with His-Ub and ATP, the reaction 
mixture was added to His-tag purification nickel resin to pull-down ubiquitinated 
proteins. The ubiquitinated proteins were then detected following Western blot analysis. 
A unique ubiquitinated band of ~36kDa was detected mainly in the wild-type mouse 
brain, in which ATP was added to the reaction mixture (Figure 4), indicating that the 
presence of MsrA and ATP are important for the formation of this Ub-bound protein. 
Consequently, the corresponding band was subjected to mass spectrometry for 
identification after in-gel tryptic digestion. Surprisingly, the sequence determination 
suggests that this 36kDa ubiquitinated protein comes from the 14-3-3 protein family 
(Figure 5). Moreover, glycine residues were found on the lysine sites of the digested 
peptides, indicating that 14-3-3 was ubiquitinated and these lysine residues are indeed 
ubiquitin binding sites. 
3.5. Interactions between ubiquitin, αSyn, 14-3-3 proteins in wild-type and 
MsrA knockout mouse brains 
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        14-3-3 proteins are known binding partners of αSyn. Hence, we hoped to 
further investigate the role of MsrA in the ability of 14-3-3 to affect the ubiquitination 
and degradation of αSyn. Immunoprecipitation experiments followed by Western blot 
analyses were performed using brain extracts to identify the interaction among αSyn, 
Ub, and 14-3-3 proteins. MsrA knockout brain (M) showed lower levels of 
ubiquitinated and degraded band products of both αSyn and 14-3-3 proteins compared 
with wild-type brain (W) (Figure 6A). These results suggest that both αSyn and 14-3-
3 proteins are ubiquitinated and degraded more efficiently in the presence of MsrA. 
Immunoprecipitation with anti-14-3-3 antibody confirmed that 14-3-3 is indeed more 
ubiquitinated and Ub-dependent degraded (as reflected by the presence of mid to low 
size molecular mass bands) in the wild-type strain. Furthermore, the fact that αSyn and 
ubiquitinated protein separation pattern in the wild-type strain looked very similar 
(following immunoprecipitation with 14-3-3 antibody) suggests that ubiquitination 
and/or associated degradation of αSyn are both MsrA and 14-3-3 depended. (Figure 
6B). Next, to show the dependence on ATP in this process, a comparative experiment 
± ATP was performed followed by 14-3-3 immunoprecipitation. The wild-type brain 
showed an enhanced αSyn degradation and ubiquitination in the presence of ATP. 
However, no change was observed in the levels of the monomer and the dimer forms 
of αSyn and no mid-to-low molecular mass ubiquitinated proteins were present in the 
MsrA knockout brain. This phenomenon suggests again that MsrA is important for the 
ubiquitination-dependent degradation of αSyn. An enhanced non-ubiquitinated αSyn 
band showed up when external ATP was added to the MsrA knockout mouse brain 
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extract, maybe due to an increased stability of αSyn phosphorylation caused by a 
decreased clearance of 14-3-3 proteins (Figure 6C). This correlates with a previous 
suggestion that 14-3-3 protect the phosphorylated αSyn from being dephosphorylated 
at the presence of high DA levels (like in the case of MsrA KO brain) [70, 73]. The 
expression levels of αSyn and 14-3-3 proteins were similar (Figure 6D), eliminating 
the possibility that lower expression of either of these proteins may account for their 
absence in the MsrA knockout brain.  
3.6. Expression and purification of A53T αSyn in yeast and its effect on the 
organism’s protein ubiquitination  
To confirm the effect of MsrA on αSyn ubiquitination, we expressed the 
mutant A53T αSyn in wild-type (WT) and msrA null (KO) yeast strains. Nickel resin 
chromatography was conducted to pull down the His-tagged αSyn. Similar expression 
levels were found in both strains, and the quantity of the pulldown product was also the 
same in the two strains (Figure 7A). msrA null mutant strain showed significantly lower 
total ubiquitination level and αSyn ubiquitination level (Figure 7B) compared with 
wild-type expressing A53T αSyn cells. These results provide further evidence for the 
hypothesis that MsrA plays an important role in the ubiquitination of αSyn in-vivo 





Figure 1. MsrA-dependent αSyn molecular mass modification by yeast extract. 
Three types of yeast strains, wild-type (WT), msrA null (KO), and msrA overexpression 
(OP) were made and grown in synthetic minimal media. Mid-logarithmic cells were 
harvested and extracted using PBS, yeast protease inhibitors cocktail, and MG132 
proteasome inhibitor. (A) Equal amounts of extracted proteins of each yeast type were 
incubated for a period of 30 minutes at 37°C in the presence of either native αSyn, 
A53T mutant of αSyn, or A30P mutant of αSyn, ubiquitin (Ub), ATP and MgCl2. At the 
end of the incubation, the extracts were subjected to western blot analysis using anti α-
syn antibody. (B) Showing the dependency of the external additions of both ATP and 
Ub on the enhancement of A53T α-syn molecular mass increase (as described in panel 
A) for the KO and OP extracts. Similar results were obtained for the native and A30P 
αSyn (data not shown). (C) Showing the net effect of ATP (that contains MgCl2) and 
ATP plus external Ub additions on the enhancement of A53T α-syn molecular mass 
increase (as described in panel A) for the OP extract only. Similar results were obtained 
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for the native and A30P αSyn (data not shown). The molecular mass markers fit with 






Figure 2. Degradation of α-synuclein in an ex-vivo system of yeast. The αSyn types: 
native (N) or A53T mutant (A53T), were incubated with yeast extracts of either msrA 
null (KO) or msrA overexpression (OP) for a period of 30 minutes at 37°C, in the 
presence or absence of ubiquitin (Ub, which contained also ATP and MgCl2). At the end 
of the incubation, the extracts were subjected to western blot analysis using anti-αSyn 





Figure 3. Competition on Parkin auto-ubiquitination by MsrA. Recombinant 
proteins were added to a reaction mixture as shown in the figure (details are described 
in Chapter 2). The reaction mixtures were incubated for a period of 30 min at 37°C.  
The reactions were stopped by adding SDS-gel-electrophoresis sample buffer, followed 






Figure 4. Detection of ubiquitinated proteins in extracts of wild-type (W) and 
MsrA knockout (M) mouse brains. Brain extracts were made in PBS in the presence 
of protease and proteasome inhibitors. Equal amounts of protein extracts were 
incubated with recombinant His-tagged ubiquitin (Ub) ± ATP and MgCl2 for or a period 
of 30 min at 37°C. The reactions were stopped by adding SDS-gel-electrophoresis 
sample buffer, followed by western blot analysis using anti-Ub antibody. kDa, 








Figure 5. Identification of a protein that its ubiquitination is enhanced by MsrA.  
The 36kDa ubiquitinated protein (~28kDa; + 1 Ub molecule = 36kDa) identity with 
descending priority is: 1) 14-3-3 zeta, also known as Ywhaz 2) 14-3-3 gamma 3) 14-3-
























Figure 6. Interactions between Ub, αSyn, and 14-3-3 proteins in extracts of wild-
type (W) and MsrA knockout (M) mouse brains. Immunoprecipitation (IP) 
experiments (A-C) were performed on brain extracts, followed by Western blot (WB) 
using the indicated protein antibodies, as described in Section 2. kDa, molecular mass 
markers. (D) Relatively high expression levels αSyn and 14-3-3 proteins in extracts of 







Figure 7. Expression and purification A53TSyn in yeast and its effect on protein 
ubiquitination of wild-type (WT) and msrA null (KO) yeast extracts. Yeast strains 
were grown and extracts were made according to the procedures described in Section 
2. (A) Expression levels of αSyn in wild-type (WT) and MsrA knockout (KO) strains, 
as judged by western blot analysis using anti-αSyn antibody (note that the molecular 
mass of αSyn is higher than expected due to the presence of His-tag at the C-terminal 
region of the protein). (B) His-ubiquitin pulldown, purifying the proteins harboring His-







CHAPTER 4: DISCUSSION 
Twenty years ago, αSyn was found to be the main component of Lewy bodies, 
the pathological hallmark of PD [11]. From then on, numerous efforts were made on 
the identification of αSyn’s role in PD pathogenesis. However, the precise mechanisms 
of αSyn aggregation and degradation are still unclear. Recent studies revealed that both 
UPS and autophagy pathways are involved in the clearance of αSyn, and that the 
binding between 14-3-3 proteins and αSyn is contributed to the aggregation of αSyn 
[67]. Previously, our lab revealed an enhanced DA level and reduced αSyn clearance in 
MsrA knockout mouse brain and clearance of αSyn was also inhibited in msrA null 
mutant yeast cells expressing αSyn [70, 73]. The observations described above suggest 
potential interactions among αSyn, ubiquitin system, 14-3-3 proteins, and MsrA. Thus, 
our current study is focused on the molecular mechanism underlying the decreased 
αSyn clearance in MsrA knockout eukaryote models and the effect of MsrA on the 
interactions among αSyn, Ub system, and 14-3-3 proteins. Our studies have 
demonstrated for the first time that (1) MsrA is involved in the mass modification of 
αSyn in a Ub- and ATP-dependent manner (Figure 1). (2) MsrA is important for Ub-
dependent clearance of both native αSyn and A53T mutant αSyn monomers (Figure 2). 
(3) MsrA plays an important role in the ubiquitination of αSyn and it inhibits Parkin’s 
autoubiquitination (a known E3 ubiquitin ligase of αSyn), suggesting that it may 
function as an E3 ubiquitin ligase in the Ub-dependent degradation of αSyn (Figure 3). 
(4) Ubiquitinated 14-3-3 proteins are detected with dependency on the presence of 
MsrA and ATP (Figure 4, 5). (5) Both αSyn and 14-3-3 proteins are ubiquitinated and 
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degraded more efficiently in the presence of MsrA (Figure 6). (6) The ubiquitination 
and/or associated degradation of αSyn are both MsrA and 14-3-3 depended (Figure 6).  
Yeast and humans share many key cellular pathways, such as membrane 
trafficking, protein aggregation, mitochondrial dysfunction, oxidative stress, 
transcriptional deregulation, and regulated protein turnover, allowing performing 
studies on the cellular potential to degrade protein aggregates. The budding yeast 
Saccharomyces cerevisiae is an established model to study αSyn aggregation and 
toxicity [76-78]. Various post-translational modifications were related to the 
aggregation, distribution, and degradation of αSyn, and several of these modification 
sites are conserved from yeast to human [79]. Thus, in our initial study, we used this 
yeast model to investigate the effect of MsrA on αSyn structural changes. The msrA OP 
strain shows a higher level of Ub- and ATP-dependent αSyn aggregation in all types of 
synucleins compared with msrA KO strain (Figure 1). However, there is much less 
difference between WT cells and msrA KO cells in the aggregation pattern of native 
αSyn or A30P αSyn, presumably due to relatively low MsrA activity in WT cells and a 
lower capability for native or A30P αSyn to form aggregates. Based on these 
considerations and the fact that msrA KO strain has an identical genomic background 
as msrA OP strain (which differs only by containing a MsrA overexpressing plasmid), 
we used these two strains to further investigate the effect of MsrA on αSyn, 14-3-3 and 
ubiquitination. Our results showed that ubiquitin promotes the clearance of both types 
of αSyn (native and A53T) monomers in msrA OP strain but not in msrA KO strain. 
Interestingly, in the presence of ubiquitin, msrA OP strain also showed reduced 
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degradation of the native αSyn dimer (Figure 2), suggesting that the degradation 
pathways are not always the same for the different formations of αSyn. It also indicates 
that MsrA may play different roles in multiple systems. The observation above and 
some accumulated evidence in Archaea (unpublished data) showed an inspiring 
possibility that MsrA may be involved in ubiquitination-associated degradation. Indeed, 
we found that MsrA inhibits the auto-ubiquitination of Parkin (Figure 3), possibly due 
to the competition for Ub binding between MsrA and Parkin. This result suggests a 
direct interaction between MsrA and Ub, as well as the similarity of function between 
MsrA and Parkin. The possibility that MsrA functions as an E3 ubiquitin ligase has been 
suggested to be the case for the Acraea MsrA (unpublished data). Although auto-
ubiquitination of MsrA was not observed in this experiment, it is not ruling out the 
possibility that MsrA cannot function as an E3 ligase since this process is highly 
dynamic and other undetermined factors are needed for stabilizing the binding between 
MsrA and Ub (e.g. a suitable E2 type for MsrA). 
The observations above clearly suggest that MsrA plays an important role in 
the Ub-dependent αSyn degradation. However, do 14-3-3 proteins also play a role in 
this process? To answer this question, we created an ex-vivo system using wild-type 
(W) and MsrA knockout (M) mouse brain extracts. Following His-ubiquitinated protein 
pull-down experiments in conjunction with mass spectrometry analyses, ubiquitinated 
14-3-3 proteins were identified only in the presence of W extract and ATP (Figure 4, 
5). This data fit very well to our anticipation that 14-3-3 proteins are ubiquitinated by 
MsrA for degradation. The protein 14-3-3 can bind αSyn in the presence of high levels 
38 
 
of DA and protect it from being degraded via the Ub system, through binding to a 
specific phosphorylated Ser129 of αSyn [67]. Thus, the presence of MsrA enhances 
αSyn degradation by eliminating this protective effect of 14-3-3 through ubiquitination 
and degradation. The aggregated forms of αSyn in the presence of MsrA (Figure 1) 
may be indicative of enhanced ubiquitination of αSyn by other ligases that otherwise is 
inhibited in the absence of MsrA, allowing a sustained protective effect of 14-3-3 
against Ub-dependent degradation of αSyn. However, no ubiquitinated αSyn was 
detected in whole brain extracts of either W or M strain (Figure 4). This fact suggests 
that the condition favoring αSyn ubiquitination and degradation in the brain is affected 
by other factors besides MsrA, which is more complicated than in yeast. To further 
investigate the role of MsrA in the ability of 14-3-3 to affect the ubiquitination and 
degradation of αSyn, immunoprecipitation experiments followed by Western blot 
analyses were performed using brain extracts to identify the interaction among αSyn, 
Ub, and 14-3-3 proteins. It is clear that interactions exist among αSyn, Ub, and 14-3-3 
proteins and MsrA plays an important role in the regulation of these interactions. 
(Figure 6A, B) Interestingly, an enhanced non-ubiquitinated αSyn band showed up 
when external ATP was added to the MsrA knockout mouse brain extract, probably due 
to enhanced αSyn phosphorylation that caused by the decreased clearance of 14-3-3 
proteins (Figure 6C). These data confirm the previous suggestion that 14-3-3 protect 
the phosphorylated αSyn from being dephosphorylated at the presence of high DA 
levels (like in the case of MsrA KO brain) [70, 73]. At last, a complementary study in 
yeast showed that the deletion of msrA gene led to lower total ubiquitination level and 
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αSyn ubiquitination level, providing further evidence for the hypothesis that MsrA 
plays an important role in the ubiquitination of αSyn in-vivo. 
To combine all the currently known information from previous studies and 
our observations, a hypothetical model for the effect of MsrA on αSyn function and 
ubiquitination processes involving 14-3-3 proteins the following schematic summary 
figure was created (Figure 8).This figure suggested events and their consequences 
could be summarized as follows: Compromised levels of the MsrA protein will lead to 
an impaired Ub-dependent 14-3-3 clearance, causing an upregulation of cellular 14-3-
3 level. This will bring about the enhanced inhibition of αSyn dephosphorylation, 
resulting in reduced Ub-dependent αSyn degradation. The latter event will eventually 
lead to αSyn dysfunction and aggregation. On the other hand, the elevated 14-3-3 level 
will also cause an increase in TH activity, giving rise to upregulated DA synthesis. 
Overwhelming cellular DA will lead to increased production of quinones and ROS, 
causing further dysfunction and aggregation of αSyn. 
According to this model, some future directions for this study could be: (1) 
further investigation on whether MsrA functions as an E3 ubiquitin ligase under certain 
conditions, establish the active site for Ub binding, and screen for its potential E2 
enzyme/s. (2) To determine which subtypes of 14-3-3 proteins are involved in the 
regulation of αSyn degradation. (3) To determine how the UPS and the autophagy 
pathways are involved in the different formations αSyn (4) Complementary 
experiments are needed to confirm the relationship between αSyn clearance and 14-3-
3 degradation. We think that the current study along with the future research directions 
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will provide more insights into the Ub-related function of MsrA in regulating αSyn 

















Figure 8. A schematic representation of hypothesized mechanism underlying the 
regulation of 14-3-3 clearance by MsrA and αSyn related PD pathogenesis. (A) 
MsrA plays an important role in the regulation of αSyn degradation through the 
ubiquitin-dependent clearance of 14-3-3 proteins. (B) Elevated levels of 14-3-3 will 
cause an increase in the activity of TH, leading to a synthesis upregulation of DA. 
Overwhelming cellular DA will lead to an increased production of quinones and ROS, 
causing further dysfunction and aggregation of αSyn, which will eventually result in 
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